A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Clinical trial NCT06483334 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06483334
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-17
- Primary completion
- 2028-03-31
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.